BR112022007488A2 - Forma cristalina de base livre de um receptor c5a de componente do complemento - Google Patents
Forma cristalina de base livre de um receptor c5a de componente do complementoInfo
- Publication number
- BR112022007488A2 BR112022007488A2 BR112022007488A BR112022007488A BR112022007488A2 BR 112022007488 A2 BR112022007488 A2 BR 112022007488A2 BR 112022007488 A BR112022007488 A BR 112022007488A BR 112022007488 A BR112022007488 A BR 112022007488A BR 112022007488 A2 BR112022007488 A2 BR 112022007488A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor
- free
- complement component
- crystalline form
- base crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932652P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/059287 WO2021092292A1 (en) | 2019-11-08 | 2020-11-06 | FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007488A2 true BR112022007488A2 (pt) | 2022-07-12 |
Family
ID=75846182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007488A BR112022007488A2 (pt) | 2019-11-08 | 2020-11-06 | Forma cristalina de base livre de um receptor c5a de componente do complemento |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11026935B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054577A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554019A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220098179A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114641289A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020378061A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022007488A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155596A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022001173A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292317A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005403A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021092292A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202305622B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020380367B2 (en) | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| CA3192880A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| JP5819730B2 (ja) * | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP6898229B6 (ja) * | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| AU2020380367B2 (en) * | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 AU AU2020378061A patent/AU2020378061A1/en not_active Abandoned
- 2020-11-06 BR BR112022007488A patent/BR112022007488A2/pt not_active IP Right Cessation
- 2020-11-06 KR KR1020227018961A patent/KR20220098179A/ko not_active Withdrawn
- 2020-11-06 IL IL292317A patent/IL292317A/en unknown
- 2020-11-06 CA CA3155596A patent/CA3155596A1/en active Pending
- 2020-11-06 US US17/091,019 patent/US11026935B2/en active Active
- 2020-11-06 JP JP2022525889A patent/JP2022554019A/ja not_active Withdrawn
- 2020-11-06 CN CN202080077446.8A patent/CN114641289A/zh active Pending
- 2020-11-06 MX MX2022005403A patent/MX2022005403A/es unknown
- 2020-11-06 EP EP20884944.8A patent/EP4054577A4/en not_active Withdrawn
- 2020-11-06 WO PCT/US2020/059287 patent/WO2021092292A1/en not_active Ceased
-
2021
- 2021-05-04 US US17/307,865 patent/US20220096453A1/en not_active Abandoned
-
2022
- 2022-05-04 CL CL2022001173A patent/CL2022001173A1/es unknown
-
2023
- 2023-04-24 US US18/305,611 patent/US20230381167A1/en not_active Abandoned
- 2023-05-25 ZA ZA2023/05622A patent/ZA202305622B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292317A (en) | 2022-06-01 |
| CL2022001173A1 (es) | 2023-02-10 |
| EP4054577A1 (en) | 2022-09-14 |
| MX2022005403A (es) | 2022-05-24 |
| CN114641289A (zh) | 2022-06-17 |
| JP2022554019A (ja) | 2022-12-27 |
| CA3155596A1 (en) | 2021-05-14 |
| ZA202305622B (en) | 2024-01-31 |
| WO2021092292A1 (en) | 2021-05-14 |
| EP4054577A4 (en) | 2023-11-29 |
| US20220096453A1 (en) | 2022-03-31 |
| KR20220098179A (ko) | 2022-07-11 |
| AU2020378061A1 (en) | 2022-05-26 |
| US20210137907A1 (en) | 2021-05-13 |
| US20230381167A1 (en) | 2023-11-30 |
| US11026935B2 (en) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007489A2 (pt) | Forma amorfa de um receptor c5a de componente do complemento | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| BR112018016671A2 (pt) | sulfonilureias e compostos relacionados e uso do mesmo | |
| PE20181016A1 (es) | Compuestos antivirales de fosfodiamida de ester de beta aminoacido | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| ZA202305622B (en) | Free base crystalline form of a complement component c5a receptor | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| MX2018010983A (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| CU20060037A7 (es) | Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| BR112014028954A2 (pt) | amidas de n-piridinila substituídas no anel como inibidores da quinase | |
| NO20083845L (no) | 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer | |
| BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| SA521421262B1 (ar) | مشتق أمين جديد حلقي غير متجانس وتركيبة صيدلانية تشتمل عليه | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي | |
| EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa | |
| MY206963A (en) | Stable polymorphic form of 6-fluoro-9-methyl-9h--carboline and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |